This review summarises highlights from a virtual symposium at the Thoracic Society of Australia and New Zealand Annual Scientific Meeting exploring the clinical validity of fractional exhaled nitric oxide in the management of severe asthma.
The symposium was opened by Assoc Prof Deborah Yates (St Vincent’s Hospital, Sydney, Australia), who also introduced the role of FeNO as a biomarker of type 2 inflammation and a prognostic factor in severe asthma. Assoc Prof Yates was joined by Prof Andrew Menzies-Gow (Royal Brompton and Harefield Hospitals, London, United Kingdom) who reviewed the clinical data and mechanism of action for dupilumab.
Please login below to download this issue (PDF)